Mechanical Characterisation of Nucleic Acids using Single Molecule Methods (MeCHaNiSM)
Forskningsprojekt, 2024 – 2028

Nucleic acid (NAs)-based therapies have started to yield major advances in the treatment of human disease. New approaches for understanding NA structure and function are required to extend the boundaries of today’s gene editing technologies, cancer therapies, and mRNA vaccines. Single-molecule techniques have revolutionised our understanding of NAs and their interactions with therapeutic oligonucleotides, small molecules, and proteins.

However, for Europe to remain competitive in this area, new expertise is urgently required in single-molecule NA analysis, which intersects the fields of physical chemistry, biophysics, NA synthesis, and computation. MeChaNiSM will train the next generation of European scientific leaders in the development and use of single-molecule biophysics techniques where they will investigate critical interrelated question regarding the structure, dynamics, function, and interactions of NAs. To do this, our Doctoral Candidates (DCs) will:
- Unravel high-resolution NA structures and intramolecular forces with modified bases
- Understand the conformation and dynamics of NAs at the single-molecule level
- Develop next-generation therapeutics for treating genetic diseases
MeChaNiSM connects world-leading researchers working in the fields of single-molecule biophysics, NA chemistry, and computational modeling with outstanding industrial partners working in complementary fields.

In addition to conducting world-class research, our DCs will understand industrial needs, have know-how in running multidisciplinary research, and will be immersed in a broad collaborative network connecting academia and industry. Our DCs will provide vital future breakthrough applications in NAs and single-molecule analysis to pharmaceutical and biotechnological industries where the design of new drugs - including NA-based therapeutics and vaccine technologies - will provide major improvements to human health.

Deltagare

Fredrik Westerlund (kontakt)

Chalmers, Life sciences, Kemisk biologi

Marcus Wilhelmsson

Chalmers, Kemi och kemiteknik, Kemi och biokemi

Samarbetspartners

AstraZeneca AB

Södertälje, Sweden

Dublin City University

Dublin, Ireland

KU Leuven

Leuven, Belgium

LUMICKS BV

Amsterdam, Netherlands

NanoTemper Technologies GmbH

Munchen, Germany

National Institute for Bioprocessing Research and Training (NIBRT)

Dublin, Ireland

Stichting VU-VUmc

Amsterdam, Netherlands

Universitat de Barcelona

Barcelona, Spain

Universiteit Utrecht

Utrecht, Netherlands

Universiteit Van Amsterdam

Amsterdam, Netherlands

Universität zu Köln

Köln, Germany

Finansiering

Europeiska kommissionen (EU)

Projekt-id: EC/HE/101168851
Finansierar Chalmers deltagande under 2024–2028

Mer information

Senast uppdaterat

2024-08-29